Beta Bionics, INC Schedule 13G passive stakes

Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 595,000 shares, representing 1.3% of Beta Bionics, Inc.'s common stock, as of June 30, 2026.

Divisadero Street Capital Management, LP and affiliated entities report beneficial ownership of 6.9% of Beta Bionics, Inc. common stock.

Eventide Asset Management, LLC, along with individuals Finny Kuruvilla and Robin C. John, have reported beneficial ownership of 5,945,488 shares, representing 13.4% of Beta Bionics, Inc.'s common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong report beneficial ownership of 2,000,000 shares, representing 4.5% of Beta Bionics, Inc. common stock.

Multiple entities and individuals associated with Farallon Capital Management have filed Schedule 13G amendments, collectively reporting significant beneficial ownership of Beta Bionics, Inc. common stock.

The Vanguard Group has reported zero beneficial ownership in Beta Bionics Inc. following an internal realignment.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 5.2% beneficial ownership stake in Beta Bionics, Inc. as of February 18, 2026.

RTW Investments, LP and Roderick Wong, M.D. have reported beneficial ownership of 5.7% of Beta Bionics, Inc.'s common stock.

Soleus Capital Management and affiliated entities, including Guy Levy, have disclosed a collective 5.8% beneficial ownership in Beta Bionics, Inc. via a Schedule 13G filing.

Wellington Hadley Harbor Aggregator IV, L.P. reports 0% beneficial ownership in Beta Bionics, Inc. common stock.

Wellington Management Group and its affiliates filed an amended Schedule 13G, reporting no beneficial ownership in Beta Bionics, Inc. common stock.

Farallon Capital Management and related entities update their Schedule 13G filing for Beta Bionics, Inc., reflecting internal management changes and associated beneficial ownership adjustments.

Multiple Farallon Capital entities and individuals have disclosed significant beneficial ownership, collectively holding 9.9% of Beta Bionics, Inc. common stock.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, reported an aggregate beneficial ownership of 8.6% of Beta Bionics, Inc.'s common stock.

The Vanguard Group has reported a 5.09% beneficial ownership stake in Beta Bionics Inc., primarily for investment purposes.

BlackRock, Inc. has reported a 6.4% beneficial ownership stake in Beta Bionics Inc. common stock as of September 30, 2025.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander jointly reported a 1.8% passive beneficial ownership in Beta Bionics, Inc. common stock.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, reported a 5.3% beneficial ownership stake in Beta Bionics, Inc. common stock.

Farallon Capital Management and its affiliates, including Zone Healthcare Holdings, report a significant passive stake in Beta Bionics, Inc., with key individuals holding up to 9.7% beneficial ownership.

Sands Capital Life Sciences Pulse Fund II, along with its affiliates, reported a beneficial ownership of 8.2% in Beta Bionics, Inc. common stock.

Morgan Stanley and its subsidiary have reported beneficial ownership of 6.8% of Beta Bionics, Inc.'s common stock as of June 30, 2025.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. filed an amendment to their Schedule 13G, restating their beneficial ownership in Beta Bionics, Inc. at 3.68%.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a beneficial ownership of 5.1% in Beta Bionics, Inc.'s common stock.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 7.6% in Beta Bionics, Inc., totaling 3,299,869 shares of common stock.

Wellington Hadley Harbor Aggregator IV, L.P. has filed an amended Schedule 13G, disclosing a 9.0% beneficial ownership stake in Beta Bionics, Inc. as of March 31, 2025.

Wellington Management Group LLP and its affiliates have disclosed a 9.0% beneficial ownership stake in Beta Bionics, Inc., holding 3,901,599 shares of common stock as of March 31, 2025.

Soleus Capital Management and its affiliated entities have disclosed a collective beneficial ownership of 8.8% of Beta Bionics, Inc.'s common stock as of March 31, 2025.

Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Ventures, LLC, and Frank M. Sands have jointly reported a 7.3% beneficial ownership stake in Beta Bionics, Inc. common stock.

Farallon Capital Management and its affiliated entities, along with key individuals, have disclosed a collective beneficial ownership of 7.9% of Beta Bionics, Inc.'s common stock, held as a passive investment.

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has reported a beneficial ownership of 11.32% in Beta Bionics, Inc. common stock, signaling a notable institutional investment.